A personalized vaccine plus standard treatment kept more melanoma from returning
☕ Includes a question for the family ↓
Melanoma treatmentPart of a story we are following · 5 articles · See every update
If you or someone you love has had melanoma removed, here is encouraging news. A personalized vaccine, added to the immunotherapy many patients already receive, kept more people free of melanoma after surgery.
In a study of 1,137 people whose stage IIB to IV melanoma had been completely removed, those who got a personalized vaccine called intismeran plus the immunotherapy drug pembrolizumab were more likely to stay free of melanoma at 24 months: 82.2% compared with 70.0% for those who got pembrolizumab alone.
How the study worked
This was a phase 3 trial, the kind used to confirm that a treatment works in a large group. Researchers randomly assigned 1,137 patients to one of two groups, and neither the patients nor the doctors knew who got the real vaccine. The results were published on November 11, 2026 in the N Engl J Med, and the median follow-up was 24.6 months, so longer follow-up will show how the benefit holds over time.
Everyone had a high-risk cutaneous (skin) melanoma that surgeons had completely removed. Everyone received pembrolizumab through an IV every 6 weeks for nine cycles. In addition, 757 people got intismeran shots in the muscle every 3 weeks for nine doses, and 380 got placebo shots that looked the same. The study was funded by Merck Sharp and Dohme and Moderna.
What is a personalized vaccine?
This kind of vaccine is not a one-size-fits-all shot. It is built around the specific changes found in a patient’s own tumor, called neoantigens. The goal is to train your immune system’s T-cells, the cells that find and fight threats, to recognize those changes. It can also strengthen T-cell responses your body already has.
Think of it like handing your immune system a clear photo of exactly what to look for.
What they found
The main goal was to see how long people stayed free of melanoma coming back. At 24 months, 82.2% of people in the vaccine group had no recurrence, compared with 70.0% in the placebo group.
The vaccine also made a difference for melanoma spreading to other parts of the body. At 24 months, 88.5% of people in the vaccine group had no distant spread, compared with 80.2% in the placebo group.
Timing matters here. In the first 6 months, the two groups looked about the same. After that, the gap opened up, and the vaccine group had clearly fewer recurrences. The researchers concluded that adding intismeran to pembrolizumab significantly extended the time people stayed free of recurrence and free of distant spread.
What about side effects?
Serious side effects (grade 3 or higher) happened in 23.6% of people in the vaccine group and 20.3% of people in the placebo group, so the numbers were close. Eight people (1.1%) in the vaccine group died from an adverse event, and five of those deaths happened before they had received any intismeran.
What you can do today
Grab a notebook or your phone and write down three questions for your next follow-up visit: what stage your melanoma was, what treatment after surgery is right for you, and whether any trials like this one are open to you. You can also read the trial’s public listing, ClinicalTrials.gov NCT05933577, to see how it was set up.
Talk about it at home
Your immune system has special cells called T-cells that act like tiny guards, always checking for anything that does not belong. Scientists made a vaccine from the unique marks found on one person’s own tumor, so the guards know exactly what to look for. Then they compared two groups chosen by chance, and only one group got the real vaccine.
Look up together how a detective dog or a security guard learns to recognize one particular thing in a crowd, and then talk about how that is like showing your body a clear photo of what to look for.
Try it at home
Keep exploring
Copies this article and its questions so you can paste them into ChatGPT, Claude, Gemini or the AI you use, and keep the conversation going.
Cite this article
Mongevity Desk. A personalized vaccine plus standard treatment kept more melanoma from returning. Mongevity. Published November 11, 2026. Accessed November 22, 2026. https://mongevity.science/cancer/2026/11/personalized-vaccine-pembrolizumab-melanoma-recurrence/Mongevity Desk. A personalized vaccine plus standard treatment kept more melanoma from returning [Internet]. Mongevity; 2026 Nov 11 cited 2026 Nov 22]. Available from: https://mongevity.science/cancer/2026/11/personalized-vaccine-pembrolizumab-melanoma-recurrence/Mongevity Desk. (2026, November 11). A personalized vaccine plus standard treatment kept more melanoma from returning. Mongevity. https://mongevity.science/cancer/2026/11/personalized-vaccine-pembrolizumab-melanoma-recurrence/
<a href="https://mongevity.science/cancer/2026/11/personalized-vaccine-pembrolizumab-melanoma-recurrence/">A personalized vaccine plus standard treatment kept more melanoma from returning</a>
Free to share or quote with credit and a link.
Questions and answers
- What is intismeran?
- It is a personalized vaccine made around the specific changes in a patient's own tumor. It is designed to train the immune system's T-cells to recognize them.
- Who was in the study?
- 1,137 people whose stage IIB to IV skin melanoma had been completely removed by surgery. All of them received pembrolizumab.
- How much did the vaccine help?
- At 24 months, 82.2% of people who got the vaccine plus pembrolizumab had no recurrence, compared with 70.0% who got pembrolizumab alone.
- Did the vaccine cause more serious side effects?
- Serious side effects were close between the groups: 23.6% with the vaccine and 20.3% with placebo.



